@article{ref1,
title="Incidence of adverse psychiatric events during treatment of inflammatory bowel disease with biologic therapies: a systematic review",
journal="Crohn's and colitis 360",
year="2020",
author="Jain, Avni and Marrie, Ruth Ann and Shafer, Leigh Anne and Graff, Lesley A. and Patten, Scott B. and El-Gabalawy, Renee and Sareen, Jitender and Bolton, James M. and Fisk, John D. and Bernstein, Charles N.",
volume="2",
number="1",
pages="otz053-otz053",
abstract="We conducted a systematic review and a fixed-effects meta-analysis to determine whether incident adverse psychiatric events (APE) including depression, anxiety, psychosis, or suicide were associated with biologic therapy in IBD. Six randomized controlled trials and a cohort study met criteria, reporting an incidence of APE in 4,882 patients. The risk difference per 100 person-months of any APE with a biologic medication was 0.01 (95% confidence interval = 0.00-0.02). There was insufficient evidence available in randomized controlled trials to conclude that biologic therapy in IBD is associated with an increased incidence of APE.<br><br>© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.<p /> <p>Language: en</p>",
language="en",
issn="2631-827X",
doi="10.1093/crocol/otz053",
url="http://dx.doi.org/10.1093/crocol/otz053"
}